A novel statistical test for treatment differences in clinical trials using a response-adaptive forward-looking Gittins Index Rule

6Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The most common objective for response-adaptive clinical trials is to seek to ensure that patients within a trial have a high chance of receiving the best treatment available by altering the chance of allocation on the basis of accumulating data. Approaches that yield good patient benefit properties suffer from low power from a frequentist perspective when testing for a treatment difference at the end of the study due to the high imbalance in treatment allocations. In this work we develop an alternative pairwise test for treatment difference on the basis of allocation probabilities of the covariate-adjusted response-adaptive randomization with forward-looking Gittins Index (CARA-FLGI) Rule for binary responses. The performance of the novel test is evaluated in simulations for two-armed studies and then its applications to multiarmed studies are illustrated. The proposed test has markedly improved power over the traditional Fisher exact test when this class of nonmyopic response adaptation is used. We also find that the test's power is close to the power of a Fisher exact test under equal randomization.

Cite

CITATION STYLE

APA

Barnett, H. Y., Villar, S. S., Geys, H., & Jaki, T. (2023). A novel statistical test for treatment differences in clinical trials using a response-adaptive forward-looking Gittins Index Rule. Biometrics, 79(1), 86–97. https://doi.org/10.1111/biom.13581

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free